BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Endostar readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Endostar\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06747169-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Endostar: Phase 2 readout est. (NCT06747169)
DESCRIPTION:Endostar\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effica
 cy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Loc
 ally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lu
 ng Cancer: a Single-arm\, Multicenter Clinical Study\nEstimated primary co
 mpletion: 17 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/endostar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06747169
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06059261-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Endostar: Phase 2 readout est. (NCT06059261)
DESCRIPTION:Endostar\, phase 2.\nStudy: Envafolimab Combined With Chemoradi
 otherapy and Recombinant Human Endostatin for LA-NPC.\nEstimated primary c
 ompletion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/endostar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06059261
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818304-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Endostar: Phase 2 readout est. (NCT07818304)
DESCRIPTION:Endostar\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SRT Co
 mbined With Envafolimab and Endostar in the First-line Treatment of Advanc
 ed NSCLC\nEstimated primary completion: April 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/endostar#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07818304
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841106-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Endostar: Phase 2 readout est. (NCT07841106)
DESCRIPTION:Endostar\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Early 
 Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing 
 Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases\nEstimated pr
 imary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/endostar#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07841106
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06611826-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Endostar: Phase 2 readout est. (NCT06611826)
DESCRIPTION:Endostar\, phase 2.\nStudy: GEP Combined With Radiotherapy in N
 on-locally Treatable Recurrent NPC\nEstimated primary completion: 30 Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/endostar#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06611
 826
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965231-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Endostar: Phase 2 readout est. (NCT06965231)
DESCRIPTION:Endostar\, phase 2.\nStudy: Perioperative Toripalimab and Endos
 tatin for Stage II Melanoma: A Phase II Trial\nEstimated primary completio
 n: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 endostar#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06965231
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794488-2160@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Endostar: Phase 2 readout est. (NCT07794488)
DESCRIPTION:Endostar\, phase 2.\nStudy: Platinum-Free Regimen in Nasopharyn
 geal Carcinoma\nEstimated primary completion: 30 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/endostar#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07794488
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
